Verastem’s KRAS Inhibitor Demonstrates Early Efficacy in Pancreatic Cancer Trials

I share in the deep sorrow over the loss of our colleague Helen Branswell. She was a kind, meticulous, brilliant, and inspiring individual. Thank you, Helen.

The need-to-know this morning

• Privately held U.K. biotech OMass Therapeutics raised $310 million to support the clinical development of a drug to treat congenital adrenal hyperplasia, an inherited endocrine disorder.
• The investment firm Orbimed raised nearly $3 billion for two new private‑equity funds that will invest in U.S., European and Asian health‑care companies.

Investor: China’s biotech boom threatens U.S. venture capital

From STAT’s Allison DeAngelis: The rise of Chinese biotech is not only affecting U.S. companies; it is also threatening venture‑capital firms, warns one investor.

Source link